ALX1-11

DRUG3 trials

Sponsors

Shire

Conditions

Osteoporosis

Phase 2

A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

CompletedNCT00172107

ShireOsteoporosis

Start: 1995-05-18End: 1997-03-24Updated: 2021-05-17

Phase 3

Open Label Extension

CompletedNCT00172120

ShireOsteoporosis

Start: 2005-01-10End: 2006-10-27Updated: 2021-05-17

TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis

CompletedNCT00172081

ShireOsteoporosis

Start: 2000-04-27End: 2003-11-07Updated: 2021-05-14

Related Papers

Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study.

2010-10-0512 citations